Literature DB >> 19018458

Zoledronic acid in treatment of bone lesions by Langerhans cell histiocytosis.

Liliana Montella1, Carmela Merola, Geraldina Merola, Luigi Petillo, Giovannella Palmieri.   

Abstract

Langerhans cell histiocytosis (LCH) is a rare disease, probably an atypical myeloproliferative syndrome, with variable clinical presentation and behavior. In this report, we focus on bone involvement by LCH and treatment with zoledronic acid in six patients as they progressed after chemotherapy and radiotherapy. Zoledronic acid appeared safe and produced significant relief in pain.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19018458     DOI： 10.1007/s00774-008-0001-2

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN： 0914-8779            Impact factor:   2.626


  11 in total

1.  Treatment of Langerhans cell histiocytosis with pamidronate.

Authors:  R P Farran; E Zaretski; R M Egeler
Journal:  J Pediatr Hematol Oncol       Date:  2001-01       Impact factor: 1.289

2.  Pamidronate for bone pain from osteolytic lesions in Langerhans'-cell histiocytosis.

Authors:  K Arzoo; S Sadeghi; V Pullarkat
Journal:  N Engl J Med       Date:  2001-07-19       Impact factor: 91.245

3.  Bisphosphonate induces remission of refractory osteolysis in langerhans cell histiocytosis.

Authors:  Junji Kamizono; Yosuke Okada; Akira Shirahata; Yoshiya Tanaka
Journal:  J Bone Miner Res       Date:  2002-11       Impact factor: 6.741

4.  Imatinib mesylate for cerebral Langerhans'-cell histiocytosis.

Authors:  Liliana Montella; Luigi Insabato; Giovannella Palmieri
Journal:  N Engl J Med       Date:  2004-09-02       Impact factor: 91.245

5.  Differential In situ cytokine profiles of Langerhans-like cells and T cells in Langerhans cell histiocytosis: abundant expression of cytokines relevant to disease and treatment.

Authors:  R M Egeler; B E Favara; M van Meurs; J D Laman; E Claassen
Journal:  Blood       Date:  1999-12-15       Impact factor: 22.113

6.  Langerhans cell histiocytosis in the maxillofacial area in adults. Report of three cases.

Authors:  José Antonio García de Marcos; Alicia Dean Ferrer; Francisco Alamillos Granados; Juan José Ruiz Masera; Gracia Barrios Sánchez; Ana Isabel Romero Ortiz; José María Calderón Bohórquez; Borja Valenzuela Salas
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2007-03-01

7.  A randomized trial of treatment for multisystem Langerhans' cell histiocytosis.

Authors:  H Gadner; N Grois; M Arico; V Broadbent; A Ceci; A Jakobson; D Komp; J Michaelis; S Nicholson; U Pötschger; J Pritchard; S Ladisch
Journal:  J Pediatr       Date:  2001-05       Impact factor: 4.406

8.  Langerhans'-cell histiocytosis in adults.

Authors:  I Baumgartner; A von Hochstetter; B Baumert; U Luetolf; F Follath
Journal:  Med Pediatr Oncol       Date:  1997-01

Review 9.  Bisphosphonates: preclinical review.

Authors:  Jonathan R Green
Journal:  Oncologist       Date:  2004

10.  Skeletal Langerhans cell histiocytosis in children: permanent consequences and health-related quality of life in long-term survivors.

Authors:  Loretta M S Lau; Kyra Stuurman; Sheila Weitzman
Journal:  Pediatr Blood Cancer       Date:  2008-03       Impact factor: 3.167
View more
  8 in total

1.  Distinctive growth pattern in a patient with a delayed diagnosis of Langerhans' cell histiocytosis.

Authors:  Athanasios D Anastasilakis; Gregory A Kaltsas; Georgios Delimpasis; Ludwig Wilkens; George Kanakis; Polyzois Makras
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

2.  Treatment of Langerhans cell histiocytosis bone lesions with zoledronic acid: a case series.

Authors:  Shanthi Sivendran; Harold Harvey; Allan Lipton; Joseph Drabick
Journal:  Int J Hematol       Date:  2011-04-26       Impact factor: 2.490

Review 3.  Transplantation in rare lymphoproliferative and histiocytic disorders.

Authors:  Alexis Cruz-Chacon; John Mathews; Ernesto Ayala
Journal:  Cancer Control       Date:  2014-10       Impact factor: 3.302

4.  Bisphosphonates significantly increase the activity of doxorubicin or vincristine against canine malignant histiocytosis cells.

Authors:  S D Hafeman; D Varland; S W Dow
Journal:  Vet Comp Oncol       Date:  2011-05-18       Impact factor: 2.613

5.  Bisphosphonates in Langerhans Cell Histiocytosis: An International Retrospective Case Series.

Authors:  Deepak Chellapandian; Polyzois Makras; Gregory Kaltsas; Cor van den Bos; Lamia Naccache; Raajit Rampal; Anne-Sophie Carret; Sheila Weitzman; R Maarten Egeler; Oussama Abla
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-07-01       Impact factor: 2.576

Review 6.  Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net.

Authors:  Michael Girschikofsky; Maurizio Arico; Diego Castillo; Anthony Chu; Claus Doberauer; Joachim Fichter; Julien Haroche; Gregory A Kaltsas; Polyzois Makras; Angelo V Marzano; Mathilde de Menthon; Oliver Micke; Emanuela Passoni; Heinrich M Seegenschmiedt; Abdellatif Tazi; Kenneth L McClain
Journal:  Orphanet J Rare Dis       Date:  2013-05-14       Impact factor: 4.123

7.  Dendritic Cells Cause Bone Lesions in a New Mouse Model of Histiocytosis.

Authors:  Frédéric Grosjean; Sonia Nasi; Pascal Schneider; Véronique Chobaz; Alexandra Liu; Vanessa Mordasini; Kristell Moullec; Paolo Vezzoni; Christine Lavanchy; Nathalie Busso; Hans Acha-Orbea; Driss Ehirchiou
Journal:  PLoS One       Date:  2015-08-06       Impact factor: 3.240

Review 8.  Bone metabolism in Langerhans cell histiocytosis.

Authors:  Athanasios D Anastasilakis; Marina Tsoli; Gregory Kaltsas; Polyzois Makras
Journal:  Endocr Connect       Date:  2018-07-02       Impact factor: 3.335
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.